BioVie to Present Bezisterim Longevity Data at Aging Research Meeting

BioVie Inc., a clinical-stage biotechnology company specializing in innovative therapies for neurological, neurodegenerative disorders, and advanced liver disease, has announced a significant presentation at the upcoming 11th Aging Research and Drug Discovery Meeting (ARDD 2024). This event is set to take place from August 26-30, 2024, in Copenhagen, Denmark. The company's presentation will focus on the impact of its lead drug candidate, bezisterim (NE3107), particularly in the context of biological aging, Alzheimer's disease, and other aging-related illnesses.

The presentation, titled "Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments," will be delivered by Christopher L. Reading, BioVie's Senior Vice President of the Alzheimer’s Disease Program. Scheduled for Tuesday, August 27, from 14:40 to 15:00 CEST, the session will provide an in-depth overview of the clinical data collected thus far concerning bezisterim. The presentation aims to highlight various analyses and measurements that demonstrate bezisterim's potential to slow down the biological aging process and improve conditions related to aging.

Bezisterim is described as an orally bioavailable, blood-brain barrier-permeable, insulin-sensitizer with significant anti-inflammatory properties. Unlike other similar treatments, it is not immunosuppressive and carries a low risk of adverse drug interactions. One of the notable aspects of bezisterim is its potential efficacy against the lingering symptoms of long COVID, including fatigue and cognitive dysfunction. This is partly due to its ability to modulate the activation of NFkB, a protein complex that plays a key role in regulating the immune response to infection.

Currently, BioVie is investigating bezisterim for its therapeutic potential in both Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). In a Phase 3 study targeting patients with mild-to-moderate Alzheimer’s (NCT04669028), bezisterim demonstrated promising efficacy. Furthermore, a Phase 2 study (NCT05227820) revealed that patients treated with bezisterim exhibited improved cognitive function and favorable biomarker levels. These findings were shared at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference in December 2022. Given that approximately six million Americans suffer from Alzheimer’s, these results are particularly noteworthy.

Additionally, BioVie has completed and presented data from a Phase 2 study focused on Parkinson’s Disease (NCT05083260). This study, presented at the AD/PD™ 2023 International Conference in Gothenburg, Sweden, highlighted significant improvements in "morning on" symptoms and motor control among patients treated with a combination of bezisterim and levodopa, compared to those treated with levodopa alone. Importantly, no drug-related adverse events were reported, further underscoring the safety profile of bezisterim.

Beyond its work on neurodegenerative diseases, BioVie is also advancing treatments for advanced liver disease. The company’s Orphan drug candidate, BIV201 (continuous infusion terlipressin), is currently undergoing Phase 3 clinical testing for the treatment of ascites due to chronic liver cirrhosis. This drug has already received Fast Track status from the U.S. Food and Drug Administration (FDA) and is approved for related complications in approximately 40 countries.

BioVie Inc. continues to push the boundaries of medical science in the quest to develop effective therapies for debilitating conditions. With the upcoming presentation at ARDD 2024, the company aims to further substantiate the clinical potential of bezisterim, potentially offering new hope to patients affected by aging-related diseases.